On May 2, 2022 Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a clinical-stage biopharmaceutical company, reported that it will report financial results for the first quarter ended March 31, 2022, and provide an update on the Company’s business operations and clinical development programs on May 10, 2022, before the U.S. financial markets open (Press release, Reata Pharmaceuticals, MAY 2, 2022, View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-First-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-May-10-2022/default.aspx" target="_blank" title="View Sourcenews/news-details/2022/Reata-Pharmaceuticals-Inc.-to-Report-First-Quarter-2022-Financial-Results-and-to-Provide-an-Update-on-Clinical-Development-Programs-on-May-10-2022/default.aspx" rel="nofollow">View Source [SID1234613413]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

Reata’s management will host a conference call on May 10, 2022, at 8:30 am ET. The conference call will be accessible by dialing (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) using access code 488160. The webcast link is View Source

First quarter 2022 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at View Source and will be available for 12 months after the call. The audio recording and webcast of the conference call will be accessible for at least 90 days after the event at View Source.